352 related articles for article (PubMed ID: 22364286)
1. Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine.
Ikenberg R; Hertel N; Moore RA; Obradovic M; Baxter G; Conway P; Liedgens H
J Med Econ; 2012; 15(4):724-36. PubMed ID: 22364286
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs.
Obradovic M; Ikenberg R; Hertel N; Antoñanzas F; Gálvez R; Liedgens H
Clin Ther; 2012 Apr; 34(4):926-43. PubMed ID: 22417717
[TBL] [Abstract][Full Text] [Related]
3. Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain.
Merchant S; Noe LL; Howe A; Duff S; Gricar J; Ogden K; Mody SH
Clin Ther; 2013 May; 35(5):659-72. PubMed ID: 23587608
[TBL] [Abstract][Full Text] [Related]
4. Clinical simulation model of long-acting opioids for treatment of chronic non-cancer pain in the United States.
Neil N; Merchant S; Provenzano D; Ogden K; Mody SH
J Med Econ; 2013; 16(2):307-17. PubMed ID: 23216013
[TBL] [Abstract][Full Text] [Related]
5. Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis.
Dunlop W; Uhl R; Khan I; Taylor A; Barton G
J Med Econ; 2012; 15(3):564-75. PubMed ID: 22313329
[TBL] [Abstract][Full Text] [Related]
6. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
Gálvez R; Schäfer M; Hans G; Falke D; Steigerwald I
Adv Ther; 2013 Mar; 30(3):229-59. PubMed ID: 23475406
[TBL] [Abstract][Full Text] [Related]
7. Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain.
Coluzzi F; Ruggeri M
Curr Med Res Opin; 2014 Jun; 30(6):1139-51. PubMed ID: 24528146
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of tapentadol immediate release for the treatment of acute pain.
Kwong WJ; Ozer-Stillman I; Miller JD; Haber NA; Russell MW; Kavanagh S
Clin Ther; 2010 Sep; 32(10):1768-81. PubMed ID: 21194601
[TBL] [Abstract][Full Text] [Related]
9. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain.
Kress HG; Koch ED; Kosturski H; Steup A; Karcher K; Lange B; Dogan C; Etropolski MS; Eerdekens M
Pain Physician; 2014; 17(4):329-43. PubMed ID: 25054392
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of oxycodone with naloxone versus oxycodone alone for the management of moderate-to-severe pain in patients with opioid-induced constipation in Canada.
Goeree R; Goeree J
J Med Econ; 2016; 19(3):277-91. PubMed ID: 26535790
[TBL] [Abstract][Full Text] [Related]
11. Outcomes Associated with Treatment of Chronic Pain with Tapentadol Compared with Morphine and Oxycodone: A UK Primary Care Observational Study.
Morgan CL; Jenkins-Jones S; Currie C; Baxter G
Adv Ther; 2019 Jun; 36(6):1412-1425. PubMed ID: 30963513
[TBL] [Abstract][Full Text] [Related]
12. [Clinical and economical evaluation of new analgesics for the management of chronic pain].
Coluzzi F; Ruggeri M
Recenti Prog Med; 2014 Nov; 105(11):415-9. PubMed ID: 25424235
[TBL] [Abstract][Full Text] [Related]
13. Imputing at-work productivity loss using results of a randomized controlled trial comparing tapentadol extended release and oxycodone controlled release for osteoarthritis pain.
Lerner D; Chang H; Rogers WH; Benson C; Chow W; Kim MS; Biondi D
J Occup Environ Med; 2012 Aug; 54(8):933-8. PubMed ID: 22850352
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of tapentadol ER for managing moderate to severe chronic pain.
Afilalo M; Morlion B
Pain Physician; 2013 Jan; 16(1):27-40. PubMed ID: 23340531
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study.
Baron R; Likar R; Martin-Mola E; Blanco FJ; Kennes L; Müller M; Falke D; Steigerwald I
Pain Pract; 2016 Jun; 16(5):580-99. PubMed ID: 26095455
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of tapentadol prolonged release for moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo- and oxycodone controlled release-controlled studies.
Lange B; von Zabern D; Elling C; Dubois C
Curr Med Res Opin; 2017 Aug; 33(8):1413-1422. PubMed ID: 28537506
[TBL] [Abstract][Full Text] [Related]
17. [Tapentadol prolonged release improves analgesia, functional impairment and quality of life in patients with chronic pain who have previously received oxycodone/naloxone].
Kern KU; Krings D; Waldmann-Rex S
MMW Fortschr Med; 2014 Jul; 156 Suppl 2():54-63. PubMed ID: 25351028
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain.
Steigerwald I; Schenk M; Lahne U; Gebuhr P; Falke D; Hoggart B
Clin Drug Investig; 2013 Sep; 33(9):607-19. PubMed ID: 23912473
[TBL] [Abstract][Full Text] [Related]
19. Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial.
Baron R; Jansen JP; Binder A; Pombo-Suarez M; Kennes L; Müller M; Falke D; Steigerwald I
Pain Pract; 2016 Jun; 16(5):600-19. PubMed ID: 26554630
[TBL] [Abstract][Full Text] [Related]
20. Tapentadol prolonged release in patients with chronic low back pain: real-world data from the German Pain eRegistry.
Überall MA; Elling C; Eibl C; Müller-Schwefe GH; Lefeber C; Heine M; Heckes B
Pain Manag; 2022 Mar; 12(2):211-227. PubMed ID: 34376059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
